Eli Lilly Targets 2027 Approval for Retatrutide: The Next Big Leap in Obesity Treatment
Eli Lilly has announced plans to file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027. This timeline follows successful outcomes across two additional late-stage clinical trials, signaling a potential expansion of the company’s dominant footprint in the weight-loss and cardiometabolic health market. Expanding the Obesity Portfolio Retatrutide is … Read more




